Description

Linovio-M OD 5/500 ER is an oral antidiabetic combination therapy designed to provide effective glycemic control in patients with type 2 diabetes mellitus. It combines:

• Linagliptin (5 mg): A DPP-4 inhibitor that enhances incretin hormone activity, promoting insulin secretion and reducing glucagon release, which helps maintain blood sugar levels.
• Metformin Hydrochloride (ER) (1000 mg): A biguanide that improves insulin sensitivity, reduces hepatic glucose production, and enhances peripheral glucose uptake while minimizing gastrointestinal side effects due to its extended-release (ER) formulation.

This dual-action therapy helps in managing both fasting and postprandial blood sugar levels, reducing insulin resistance, and preventing diabetes-related complications. Linovio-M OD 5/500 ER ensures better glycemic control with fewer fluctuations, making it an ideal choice for long-term diabetes management.